Khondoker et al. showed that miR-375 and Cetuximab have synergistic anticancer effects in CRC, and downregulation of miR-375 can increase the expression of EGFR ligand connective tissue growth factor (CTGF) and enhance CTGF/EGFR/PIK3CA/AKT pathway activation. The gene discussed is PIK3CA; the disease is colorectal carcinoma.